Zobrazeno 1 - 10
of 18
pro vyhledávání: '"David Dorey"'
Autor:
Miranda Murray, Federico Pulido, Anthony Mills, Moti Ramgopal, Roger LeBlanc, Hans Jaeger, Viviam Canon, David Dorey, Sandy Griffith, Joseph Mrus, William Spreen, David Margolis
Publikováno v:
HIV Research & Clinical Practice, Vol 20, Iss 4-5, Pp 111-122 (2019)
Background: Long-acting (LA) injectable antiretroviral therapy (ART) is a novel modality currently under development as an alternative to daily oral ART. Objective: The LATTE-2 study (ClinicalTrials.gov identifier NCT02120352) showed that cabotegravi
Externí odkaz:
https://doaj.org/article/f6a3b93b9b2d4775a89b193f0be7bb9a
Autor:
Veerle Van Eygen, David A. Margolis, Marty St. Clair, Jerry Jeffrey, Daniel R. Kuritzkes, Michael Aboud, Jan van Lunzen, Yongwei Wang, William Spreen, Christine L. Talarico, Mark Baker, Kati Vandermeulen, Amy Cutrell, Carlo Federico Perno, Jonathan M. Schapiro, David Dorey, Susan L. Ford, Herta Crauwels, C. Thomas White, Joseph W. Polli, Romina Quercia, Simon Vanveggel, Sterling Wu, Parul Patel
Publikováno v:
AIDS (London, England)
Current antiretroviral therapy (ART) consists of a combination of two or more oral agents from at least two drug classes, such as an integrase strand transfer inhibitor (INSTI) as well as one or two nucleoside reverse transcriptase inhibitors (NRTIs)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8628b61e4e5a6408b1220516448bebf7
http://europepmc.org/articles/PMC8270504
http://europepmc.org/articles/PMC8270504
Autor:
Miranda Murray, David Dorey, Simon Vanveggel, Enrique Bernal, Anthony Mills, Jenny Huang, Sharon Walmsley, David A. Margolis, Hans Jäger, Mark S. Shaefer, Vasiliki Chounta, Marie-Aude Khuong-Josses, Krischan J Hudson, Sandy Griffith, William Spreen, Harold P. Katner, Antonio Antela, Johan Lombaard
Publikováno v:
AIDS and Behavior
The phase 3 ATLAS and FLAIR studies demonstrated that maintenance with Long-Acting (LA) intramuscular cabotegravir and rilpivirine is non-inferior in efficacy to current antiretroviral (CAR) oral therapy. Both studies utilized Patient-Reported Outcom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b688b7e4c1686a477ccac43d01accfdc
https://doi.org/10.1007/s10461-020-02929-8
https://doi.org/10.1007/s10461-020-02929-8
Autor:
Anthony Mills, Federico Pulido, Joseph M. Mrus, William Spreen, David Dorey, Viviam Canon, Moti Ramgopal, David A. Margolis, Sandy Griffith, Miranda Murray, Hans Jaeger, Roger LeBlanc
Publikováno v:
HIV Research & Clinical Practice. 20:111-122
Background: Long-acting (LA) injectable antiretroviral therapy (ART) is a novel modality currently under development as an alternative to daily oral ART.Objective: The LATTE-2 study (ClinicalTrials...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a05a2a2dffa26cb8e3e9076d6cc891e
https://doi.org/10.1080/25787489.2019.1661696
https://doi.org/10.1080/25787489.2019.1661696
Autor:
David Dorey, William Spreen, Veerle Van Eygen, Darrell H. S. Tan, Parul Patel, Kati Vandermeulen, Denis Gusev, Ronald D'Amico, Patrick Philibert, Chloe Orkin, Kimberly Y. Smith, Simon Vanveggel, Susan L. Ford, Juan González García, Vasiliki Chounta, Enrique Bernal Morell, Shinichi Oka, Herta Crauwels, Marty St. Clair, Olaf Degen, Ayesha Bassa, David A. Margolis, Cynthia Brinson, Sandy Griffith, Shanker Thiagarajah, Rodica Van Solingen-Ristea, Amy Cutrell
Publikováno v:
The lancet. HIV. 8(4)
There is a need for more convenient, less frequent treatment to help address challenges associated with daily oral HIV treatment in people living with HIV, including stigma, pill burden, drug-food interactions, and adherence. The phase 3 ATLAS and FL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35a5d8a189cc9adbd36436b7adc0c67f
https://pubmed.ncbi.nlm.nih.gov/34391566
https://pubmed.ncbi.nlm.nih.gov/34391566
Autor:
Pierre-Marie Girard, Chris Bettacchi, Amy Cutrell, Shinichi Oka, Vasiliki Chounta, Miguel de Górgolas Hernández-Mora, Cynthia Brinson, Marty St. Clair, Herta Crauwels, David Dorey, Vadim Pokrovsky, Wim Louis Julien Parys, William Spreen, Edgar T. Overton, Patrick Philibert, Kimberly Y. Smith, Johan Lombaard, Chloe Orkin, Sharon Walmsley, Peter Williams, David A. Margolis, Sandy Griffith, Susan L. Ford, Ronald D'Amico, Keikawus Arastéh, Simon Vanveggel, Parul Patel
Publikováno v:
The New England journal of medicine. 382(12)
Long-acting injectable regimens may simplify therapy for patients with human immunodeficiency virus type 1 (HIV-1) infection.We conducted a phase 3, randomized, open-label trial in which adults with HIV-1 infection who had not previously received ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37add18b32108939936be88a3b3b0400
https://pubmed.ncbi.nlm.nih.gov/32130808
https://pubmed.ncbi.nlm.nih.gov/32130808
Autor:
David Dorey, Sharon Walmsley, Johan Lombaard, Vasiliki Chounta, Harold P. Katner, William Spreen, Enrique Bernal, Sandy Griffith, David Margolis
Publikováno v:
Open Forum Infectious Diseases
Background In the phase 3 FLAIR study, switching to monthly injectable long-acting (LA) cabotegravir (CAB) + rilpivirine (RPV) was noninferior to continued daily oral dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) for the maintenance of virologic sup
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c784465ecc83f9ccea8d34283c862b41
http://europepmc.org/articles/PMC7776404
http://europepmc.org/articles/PMC7776404
Autor:
David Dorey, Joseph W. Polli, Feifan Zhang, Kati Vandermeulen, Ojesh R Upadhyay, Paula Teichner, David A. Margolis, Sandy Griffith, Parul Patel, Rodica Van Solingen-Ristea, Kenneth Sutton, Ronald D'Amico, William Spreen, Cynthia C McCoig, Sterling Wu
Publikováno v:
Open Forum Infectious Diseases
Background Cabotegravir (CAB) and rilpivirine (RPV) are under development as a novel long-acting (LA) regimen for maintenance of HIV virologic suppression. Pooled data from pivotal phase III trials demonstrated noninferiority of CAB + RPV LA given as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a08aa5af91faad03f16ec18705bc37cf
https://doi.org/10.1093/ofid/ofaa439.1215
https://doi.org/10.1093/ofid/ofaa439.1215
Autor:
Marty St. Clair, Andrew Zolopa, Mark R. Underwood, Dannae Brown, David Dorey, James F. Demarest
Publikováno v:
AIDS Research and Human Retroviruses
In the SAILING study, dolutegravir demonstrated superior virologic efficacy compared with raltegravir in treatment-experienced, integrase strand transfer inhibitor (INSTI)–naive patients with HIV-1 who harbored resistance to ≥2 antiretroviral dru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf9b85c73a0c1ce22127c4b916bf1a04
https://pubmed.ncbi.nlm.nih.gov/30525872
https://pubmed.ncbi.nlm.nih.gov/30525872
Autor:
Sandy Griffith, David Dorey, Conn M. Harrington, Paula Teichner, Mark S Shaefer, David A. Margolis, Peter Williams, Joseph W. Polli, Amy Cutrell, Ronald D'Amico, Rodica Van Solingen-Ristea, Krischan J Hudson, Joseph M. Mrus, Jenny Huang, William Spreen
Publikováno v:
Open Forum Infectious Diseases
Background Cabotegravir (CAB) and rilpivirine (RPV) are under development as a novel long-acting (LA) regimen for maintenance of HIV virologic suppression. Pooled Week 48 data from pivotal Phase 3 trials demonstrated noninferiority of CAB LA + RPV LA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6eebc96423d50ccc7ae4e54f95257f8d
http://europepmc.org/articles/PMC6809202
http://europepmc.org/articles/PMC6809202